Natera to present 20 ESMO abstracts: stock pre-market at EUR 352.20
Published on 10/19/2026 at 08:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSESMO evidence and schedule
- Natera announced on October 18, 2026, that 20 abstracts featuring its technology will be presented at ESMO.
- Natera stock is at EUR 352.20 pre-market at 8:04 a.m. CEST at Lang & Schwarz on October 19, 2026.
- The Signatera Genome assay has demonstrated an analytical limit of detection below 1 part per million.
Natera announced on October 18, 2026, that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology Annual Congress. Natera stock is at EUR 352.20 pre-market at Lang & Schwarz on October 19, 2026, at 8:04 a.m. CEST.
Pre-market price
The Lang & Schwarz quote lists a bid of EUR 350.50 and an ask of EUR 353.90. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Natera stock.
What matters today
Natera’s ESMO presentations are scheduled for October 23–26, 2026, in Madrid, Spain. The program includes 20 abstracts featuring Natera’s technology. The Signatera Genome with Phased and Structural Variants assay has demonstrated an analytical limit of detection below 1 part per million and detection below 1 part per 10 million.
ESMO oncology program
The company said the program will include four rapid oral presentations and presentations covering multiple tumor types and treatment modalities. Natera highlighted findings involving serial circulating tumor DNA testing, including a reported median lead time of more than 7.3 months over standard imaging in the ICONIC trial and treatment changes in the SAGITTARIUS trial.
Market context: Market report S&P 500.
